Pineapple Express Cannabis Company
Pineapple Express Cannabis Company develops centralized blockchain based Platform as a Service (PaaS) for the cannabis industry. The company is based in Atlanta, Georgia.
Pineapple Express Cannabis Company (PNXP) - Net Assets
Latest net assets as of October 2025: $-8.15 Million USD
Based on the latest financial reports, Pineapple Express Cannabis Company (PNXP) has net assets worth $-8.15 Million USD as of October 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($190.00K) and total liabilities ($8.34 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-8.15 Million |
| % of Total Assets | -4291.63% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Pineapple Express Cannabis Company - Net Assets Trend (2022–2025)
This chart illustrates how Pineapple Express Cannabis Company's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pineapple Express Cannabis Company (2022–2025)
The table below shows the annual net assets of Pineapple Express Cannabis Company from 2022 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-01-31 | $-2.08K | +86.95% |
| 2024-01-31 | $-15.93K | +97.07% |
| 2023-01-31 | $-544.35K | -824.12% |
| 2022-01-31 | $-58.91K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pineapple Express Cannabis Company's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 59325000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (January 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $671.57K | % |
| Total Equity | $-2.08K | 100.00% |
Pineapple Express Cannabis Company Competitors by Market Cap
The table below lists competitors of Pineapple Express Cannabis Company ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
The Carlyle Group Inc. 4.625% Subordinated Notes due 2061
NASDAQ:CGABL
|
$161.91K |
|
Data443 Risk Mitigation Inc
PINK:ATDS
|
$161.96K |
|
Sydinv Indeks Tyskland A DKK
CO:SYIITYADKK
|
$162.06K |
|
CARSALES.COM
BE:WN6
|
$162.18K |
|
rad Fic Firf Invest Infra Cdi Cp Resp Ltda
SA:BINC11
|
$161.81K |
|
Green Cross Holdings Corp. Pfd. Series 2
KQ:005257
|
$161.75K |
|
LOGAN RIDGE FIN. DL-01
F:0XL0
|
$161.59K |
|
Flamemaster Corporation
PINK:FAME
|
$161.30K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pineapple Express Cannabis Company's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -15,927 to -2,079, a change of 13,848.
- Net loss of 31,153 reduced equity.
- New share issuances of 45,001 increased equity.
- Other factors decreased equity by 0.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-31.15K | -1498.46% |
| Share Issuances | $45.00K | +2164.55% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Pineapple Express Cannabis Company's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-01-31 | $0.00 | $0.02 | x |
| 2023-01-31 | $-0.03 | $0.02 | x |
| 2024-01-31 | $0.00 | $0.02 | x |
| 2025-01-31 | $0.00 | $0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pineapple Express Cannabis Company utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -192.68%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | -594.62% | 0.43x | 0.00x | $-40.19K |
| 2023 | 0.00% | -825.31% | 2.34x | 0.00x | $9.99K |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-57.90K |
| 2025 | 0.00% | -192.68% | 0.00x | 0.00x | $-30.95K |
Industry Comparison
This section compares Pineapple Express Cannabis Company's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pineapple Express Cannabis Company (PNXP) | $-8.15 Million | 0.00% | N/A | $161.87K |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |